Abstract 74TiP
Background
VEGF and Ang2 signaling have key functions in tumor angiogenesis and have an immunosuppressive effect in the tumor microenvironment. Preclinical data show that combined inhibition of VEGF/Ang2 and PD-1 enhances the tumor microenvironment to support T-cell mediated destruction of tumor cells. BI 836880 is a humanized bispecific nanobody that targets VEGF and Ang2, and BI 754091 is an anti-PD-1 antibody. Each have shown safety and preliminary activity as monotherapy in phase I (recommended phase 2 dose [RP2D] 720 mg intravenous [iv] every 3 weeks [q3w] for BI 836880 [Caucasian pts] and 240 mg iv q3w for BI 754091 [Caucasian and Japanese pts]). An ongoing phase Ib study (NCT03468426) will determine the RP2D, safety and preliminary activity of BI 836880 + BI 754091 in Caucasian pts. The current phase I study will determine the maximum tolerated dose (MTD)/RP2D of BI 836880 alone or in combination with BI 754091 in Japanese pts with advanced solid tumors.
Trial design
This open-label, multi-center, dose-escalation trial will enroll pts with a confirmed diagnosis of advanced, unresectable and/or metastatic solid tumors (any type) whose disease is not amenable to standard therapies or where there is no therapy of proven efficacy. Pts are required to have an ECOG PS ≤ 1 and adequate organ function. The study has 2 parts: Part 1 will assess BI 836880 monotherapy and Part 2 will assess BI 836880 + BI 754091. Pts will receive BI 836880 at a starting dose of 360 mg iv q3w in Part 1 and of 120 mg iv q3w in Part 2 (in combination with BI 754091 240 mg iv q3w). Administration will continue until progressive disease, unacceptable toxicity or other withdrawal criteria. Dose escalation will be guided by Bayesian logistic regression models with overdose control in both Parts, with oversight from a safety monitoring committee. Primary endpoint is MTD/RP2D of BI 836880 alone (Part 1) and in combination with BI 754091 (Part 2). Secondary/further endpoints will document the safety, pharmacokinetics, anti-tumor activity and immunogenic response of BI 836880 alone and in combination with BI 754091. It is planned to enroll 24 pts.
Clinical trial identification
NCT03972150.
Legal entity responsible for the study
Boehringer Ingelheim.
Funding
Boehringer Ingelheim.
Disclosure
K. Yamazaki: Speaker Bureau / Expert testimony: Chugai; Speaker Bureau / Expert testimony: Takeda; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Taiho; Speaker Bureau / Expert testimony: Yakult; Speaker Bureau / Expert testimony: Ono; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Lily; Speaker Bureau / Expert testimony: Sanofi; Speaker Bureau / Expert testimony: Bayer; Speaker Bureau / Expert testimony: Merck-Serono; Speaker Bureau / Expert testimony: MSD; Speaker Bureau / Expert testimony: Bristol-Myers Squibb. T. Shimizu: Honoraria (self): Clinical Research Joint Scientific Committee Review Member for Phase 1 trials in Hong Kong; Honoraria (self): HKSAR China ; Advisory / Consultancy, Research grant / Funding (institution): Takeda Oncology; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Eli Lilly; Research grant / Funding (institution): Daiichi-Sankyo; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Eisai; Research grant / Funding (institution): Incyte; Research grant / Funding (institution): Astellas; Research grant / Funding (institution): Chordia Therapeutics; Research grant / Funding (institution): 3D-Medicine; Research grant / Funding (institution): Symbio Pharmaceuticals; Research grant / Funding (institution): PharmaMar; Research grant / Funding (institution): Five Prime; Research grant / Funding (institution): AstraZeneca ; Research grant / Funding (institution): AbbVie. T. Takahashi: Honoraria (self), Research grant / Funding (institution): AstraZeneca KK; Honoraria (self), Research grant / Funding (institution): Chugai Pharmaceutical Co., Ltd.; Honoraria (self), Research grant / Funding (institution): Eli Lilly Japan K.K.; Honoraria (self), Research grant / Funding (institution): Ono Pharmaceutical Co., Ltd.; Honoraria (self), Research grant / Funding (institution): MSD K.K.; Honoraria (self), Research grant / Funding (institution): Boehringer Ingelheim Japan, INC; Honoraria (self): Roche Diagnostics K.K.; Research grant / Funding (institution): Pfizer Japan Inc. Y. Tanaka: Full / Part-time employment: Boehringer Ingelheim. H. Myobudani: Full / Part-time employment: Boehringer Ingelheim. N. Yamamoto: Advisory / Consultancy, Research grant / Funding (institution): Eisai; Advisory / Consultancy, Research grant / Funding (institution): Takeda; Advisory / Consultancy: Otsuka; Advisory / Consultancy, Research grant / Funding (institution): Boehringer Ingelheim; Advisory / Consultancy: Cimic; Advisory / Consultancy, Research grant / Funding (institution): Chugai; Speaker Bureau / Expert testimony, Research grant / Funding (institution): BMS; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Pfizer; Speaker Bureau / Expert testimony: AstraZeneca; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Eli Lilly; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Ono; Speaker Bureau / Expert testimony: Sysmex; Research grant / Funding (institution): Astellas; Research grant / Funding (institution): Taiho; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): AbbVie; Research grant / Funding (institution): Daiichi-Sankyo; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Kyowa-Hakko Kirin; Research grant / Funding (institution): Janssen Pharma; Research grant / Funding (institution): MSD; Research grant / Funding (institution): Merck. All other authors have declared no conflicts of interest.
Resources from the same session
427P - Sahai: A restorative support to address unmet needs of women with cancer – impact on quality of life
Presenter: Poonam Maurya
Session: Poster display session
Resources:
Abstract
428P - A pilot study on comparative efficacy of tramadol or eutectic mixture of local anaesthetics (prilocaine plus lignocaine) in preventing bone marrow aspiration associated pain
Presenter: Bipinesh Sansar
Session: Poster display session
Resources:
Abstract
429P - Skin pathologic change evaluation of the patients who had EGFR inhibitor-related skin adverse events
Presenter: Sung Yong Oh
Session: Poster display session
Resources:
Abstract
430P - Emetic risk of carboplatin plus pemetrexed is higher than that of carboplatin plus paclitaxel in patients with lung cancer: A propensity score-matched analysis
Presenter: Koichi Matsuo
Session: Poster display session
Resources:
Abstract
431P - An in vitro evaluation of CYP2D6 enzymatic inhibition activities of a Chinese herbal medicine formulation (Xiang Bei Yangrong Tang) for the management of cancer-related fatigue
Presenter: Ning Yi Yap
Session: Poster display session
Resources:
Abstract
432P - Chemotherapy induced extravasation: Incidence and possible predictors
Presenter: Shalaka Somayaji
Session: Poster display session
Resources:
Abstract
433P - Prospective outcomes of adolescent and young adult (AYA) patients received treatment from a tertiary cancer hospital in Bangladesh
Presenter: Abdullah Al Mamun Khan
Session: Poster display session
Resources:
Abstract
434P - Pneumonitis induced antineoplastic agents: Mortality and risk factors in 129 consecutive cases
Presenter: Sawako Kaku
Session: Poster display session
Resources:
Abstract
435P - Telephonic communication in palliative care for better management of terminal cancer patients in rural India: An NGO based approach
Presenter: NABANITA MANDAL
Session: Poster display session
Resources:
Abstract
436P - Assessing the quality of life of Filipino cancer patients: A survey of Filipino oncologists
Presenter: Frederic Ivan Ting
Session: Poster display session
Resources:
Abstract